News

BlueRock Therapeutics will develop induced pluripotent stem cell (iPSC) therapies for treating various diseases. The funds are expected to give the new company at least four years of runway and enable

Several publications have recently reported that Lonza is in final discussions with Kohlberg Kravis Roberts (KKR) regarding the potential acquisition. The Swiss firm is of view that Capsugel

The phase III Monaleesa-2 study showed superior PFS with LEE011 plus letrozole in pre-defined patient subgroups, from de novo to bone, liver and lung metastases, compared to letrozole alone.

The move follows the Investigational New Drug application (IND) clearance from the US Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in

LpxC has been recognised as an attractive antibacterial target for more than the past 15 years; however, a lack of suitable chemical starting points has hampered its progress.

The companies signed a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is presently in phase I trials. The deal builds on the

This is the Company's third orphan drug designation request granted by the FDA. ALS is a progressive neurodegenerative motor neuron disease that affects nerve cells in the brain

The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or

The European Medicines Agency (EMA) approved XYDALBA for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. XYDALBA can be administered as either one